Cardiology · Medical Literature
Empagliflozin's Effects on Carotid Ultrasound Parameters in Type 2 Diabetes Patients Post-ST-Elevation Myocardial Infarction: A Randomized Controlled Trial.
Abstract
Patients with type 2 diabetes (T2D) and recent ST-elevation myocardial infarction (STEMI) face accelerated atherosclerosis and a high risk of recurrent cardiovascular events. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), particularly empagliflozin, offer proven cardioprotection in T2D. This study investigated the 3-month effects of empagliflozin on carotid intima-media thickness (CIMT) and Doppler hemodynamic parameters (resistive index [RI] and pulsatility index [PI]) in T2D patients post-STEMI. In this randomized clinical trial, 80 patients with T2D and a recent STEMI from Ayatollah Mousavi Hospital, Zanjan, Iran (from July to December 2025), were randomized in a 1:1 ratio to empagliflozin 10 mg daily or an identical placebo, in addition to standard therapy. The primary endpoint was the change in CIMT at 3 months, assessed using B-mode ultrasound. Secondary endpoints included changes in RI and PI, measured via Doppler ultrasound. Follow-up data were available for 78 patients (two deaths in the intervention arm, both unrelated to the study drug). In the primary intention-to-treat analysis (n=80), empagliflozin was associated with a significant reduction in left CIMT compared with controls (median change=-0.13 mm vs. -0.01; within-group P=0.002; between-group ΔCIMT P=0.004; ANCOVA-adjusted P<0.001) versus controls (-0.01 mm). A smaller though statistically significant difference was also observed for right CIMT (ΔCIMT, P=0.021; ANCOVA-adjusted P=0.006). These findings remained consistent in the per-protocol analysis. After Bonferroni correction, the reduction in left CIMT remained significant, whereas the effect on right CIMT became more modest. No significant changes were observed in RI or PI. Short-term empagliflozin suggested favorable changes in CIMT in high-risk T2D patients post-STEMI, without detectable effects on RI or PI.Iranian Registry of Clinical Trials: IRCT20230727058945N1.
Clinical relevance
In patients with type 2 diabetes who have recently experienced ST-elevation myocardial infarction, does 3 months of empagliflozin 10 mg daily added to standard therapy reduce carotid intima-media thickness (CIMT) and improve Doppler hemodynamic parameters (resistive index and pulsatility index) compared with placebo? __SNAPSHOT__ {"studyDesign":"Randomized, placebo-controlled trial (parallel-group, 1:1 allocation); described as double-blind based on 'identical placebo' language, though blinding procedures are not explicitly confirmed in the available abstract excerpt","setting":"Single center — Ayatollah Mousavi Hospital, Zanjan, Iran; enrollment from July to December 2025","sampleSize":"n=80 randomized (intervention: 40, control: 40); 78 completed follow-up (2 deaths in the intervention arm, both reported as unrelated to study drug); ITT analysis conducted on n=80","population":"Adults with established type 2 diabetes mellitus who had sustained a recent ST-elevation myocardial infarction; all received concomitant standard post-STEMI therapy. Additional inclusion/exclusion criteria not reported in available abstract excerpt.","intervention":"Empagliflozin 10 mg orally once daily added to standard therapy for 3 months","comparator":"Identical-appearing placebo once daily added to standard therapy for 3 months","primaryOutcome":"Change in carotid intima-media thickness (CIMT) at 3 months, assessed by B-mode ultrasound","followUp":"3 months","fundingSource":"Not reported in available abstract excerpt"}
Key findings
Based on the partial abstract provided, the primary intention-to-treat analysis (n=80) demonstrated a statistically significant reduction in left CIMT associated with empagliflozin compared with placebo at 3 months. Specific absolute and relative effect sizes, confidence intervals, and p-values for the primary endpoint are not reported in the available abstract excerpt and cannot be summarized without risk of fabrication. Secondary endpoints — change in resistive index (RI) and pulsatility index (PI) assessed by Doppler ultrasound — were pre-specified but their results are not available in the truncated abstract. No adverse event frequency data, NNT/NNH values, or between-group metabolic or hemodynamic data were reported in the available text. Two deaths occurred in the intervention arm during follow-up; both were attributed by investigators to causes unrelated to the study drug, though adjudication methodology is not described. All specific numeric outcomes are labeled as not reported due to abstract truncation.
Practice implications
This trial addresses a clinically meaningful and understudied question: whether SGLT2 inhibition with empagliflozin attenuates subclinical atherosclerosis progression — as indexed by CIMT and carotid Doppler hemodynamics — in a high-risk post-STEMI diabetic population. A reduction in left CIMT, if confirmed with full data, would provide mechanistic imaging evidence supporting the vascular anti-atherosclerotic actions of empagliflozin beyond glycemic control, which is biologically plausible given known effects on blood pressure, weight, vascular stiffness, and inflammation. However, several major caveats must be noted: (1) Only a partial abstract was available for review; complete results including effect magnitudes, confidence intervals, p-values, and secondary endpoint data could not be evaluated — this is a critical limitation of this summary. (2) CIMT is a surrogate imaging endpoint; its reduction does not establish a reduction in recurrent MACE, stroke, or mortality in this population. (3) The trial was conducted at a single Iranian center with 80 patients over only 3 months, severely limiting generalizability, power for secondary endpoints, and the ability to detect clinically important absolute differences. (4) The population is specific: T2D patients post-STEMI on standard therapy; findings may not extend to patients with T2D without recent ACS, or to those with different baseline CIMT levels or atherosclerotic burden. Women, patients with advanced CKD, and those with very recent versus more remote STEMI are likely underrepresented. (5) The clinical importance of any observed CIMT change at 3 months — in terms of downstream cardiovascular event reduction — cannot be established from this study alone. Practice should not change on the basis of this trial; empagliflozin is already guideline-recommended in T2D with established cardiovascular disease based on hard outcomes data (EMPA-REG OUTCOME), so this study's contribution would be mechanistic and hypothesis-generating rather than practice-changing. __LIMITATIONS__ Only a partial abstract was available; complete numerical results, confidence intervals, p-values, and secondary outcomes could not be reviewed or verified — all data reliance is on the abstract excerpt as provided by the user.,Small sample size (n=80); the trial is likely underpowered to detect modest differences in secondary Doppler endpoints (RI, PI) and to assess safety signals.,Single-center design from one Iranian tertiary hospital severely limits external validity and generalizability to broader international populations.,Short 3-month follow-up is insufficient to determine whether CIMT changes translate to clinically meaningful reductions in hard cardiovascular outcomes.,CIMT and Doppler hemodynamic indices (RI, PI) are surrogate endpoints; changes in these markers have not been validated as reliable predictors of event reduction in post-STEMI diabetic cohorts specifically.,Two deaths occurred in the intervention arm; while attributed to causes unrelated to study drug, adjudication methodology is not described, and the small sample size makes mortality interpretation unreliable.,Blinding integrity (use of 'identical placebo') is asserted but verification procedures are not described in the available excerpt.,Enrollment over a 6-month window at a single site raises potential for selection bias and insufficient representation of the full spectrum of post-STEMI T2D patients.,Confounding by concomitant standard post-STEMI medications (statins, ACE inhibitors/ARBs, antiplatelet agents, beta-blockers) and their differential effects on CIMT cannot be excluded with this sample size.,Funding source is not reported, limiting assessment of potential conflicts of interest.,Statistical versus clinical significance: even a statistically significant CIMT reduction at 3 months may not reach the threshold of clinical importance, particularly if the absolute mean difference is small relative to measurement variability. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This small single-center RCT (n=80) from Iran provides preliminary evidence suggesting that empagliflozin 10 mg daily may reduce carotid intima-media thickness at 3 months in patients with type 2 diabetes post-STEMI, consistent with proposed pleiotropic vascular effects of SGLT2 inhibition. Because only a partial abstract was available for review and numerical results could not be evaluated, and because CIMT is a surrogate endpoint with a 3-month follow-up insufficient to support practice change, these findings are best regarded as mechanistic and hypothesis-generating. Empagliflozin is already a guideline-recommended therapy in this population based on hard cardiovascular outcomes data; this study does not independently alter practice but may inform the design of larger, longer trials assessing vascular imaging endpoints.